Clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age

AP Momot,1 MG Nikolaeva,2 NN Yasafova,3 MS Zainulina,4 KA Momot,3 IA Taranenko31Altai Branch of FSBI, National Research Center for Hematology, Barnaul, Russia; 2Obstetrics and Gynecology Department with The Course in Supplementary Vocational Education at FSBI of Higher Education, Altai State Medical University, Barnaul, Russia; 3Altai Branch of FSBI, National Research Center for Hematology, Ministry of Healthcare of the Russian Federation, Barnaul, Russia; 4Saint Petersburg State-Financed Health Institution, “Maternity Hospital № 6 Named after Professor V.F. Snegirev”, Obstetrics, Gynecology and Reproductive Medicine Department, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, RussiaResearch objective: To research the association of prothrombin (factor II) activity given the prothrombin G20210A mutation carriage with its clinical manifestations as thrombotic complications.Materials and methods: A prospective clinical cohort study of 290 women of reproductive age was conducted. Two cohort groups were identified: the study group of 140 patients with prothrombin mutation G20210A genotype and the control group of 150 women with G20210G genotype.Results: The prothrombin G20210A mutation carriage is associated with the risk of thrombotic complications compared to the wild G20210G type (RR =17.1; p